Avanir Pharmaceuticals Announces Patient Assistance Program For NUEDEXTA

ALISO VIEJO, Calif., June 5, 2012 /PRNewswire via COMTEX/ — Avanir Pharmaceuticals, Inc. today announced details of its Patient Assistance Program for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate). The Patient Assistance Program is designed to help patients with a diagnosis of pseudobulbar affect which meet established program criteria gain access to NUEDEXTA free of charge.

“NUEDEXTA is the first and only FDA approved medication indicated for pseudobulbar affect. Avanir’s goal is to ensure that cost is not a barrier to any person who may benefit from this important medication, regardless of their level of income or healthcare coverage,” said Rohan Palekar, chief commercial officer at Avanir Pharmaceuticals. “To that end, we are pleased to offer this new Patient Assistance Program as part of our comprehensive offering of patient support services.”

This new program complements two other existing financial assistance programs currently available for patients insured by commercial health plans or Medicare Part D. With the addition of the Patient Assistance Program for patients without prescription drug coverage, Avanir now offers financial assistance for most people needing access to NUEDEXTA.

The new program, which launched in May 2012, provides eligible patients with a 6-month supply of drug, free of charge to help ensure access to NUEDEXTA. Program participants may qualify for ongoing assistance subject to periodic verification of eligibility.

..

 Please note that all comments are moderated.